aUniversity of Pittsburgh, PA;

bFred Hutchinson Cancer Research Center, Seattle, WA;

cWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa;

dUniversity of Washington, WA;

eCurrently, Gilead Sciences, Foster City, CA; and

fUniversity of Zimbabwe, Harare, Zimbabwe.

Correspondence to: Urvi M. Parikh, PhD, S830 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261 (e-mail: [email protected]).

The MTN-025/HOPE trial was designed and implemented by the Microbicide Trials Network funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the US National Institutes of Health. The International Partnership for Microbicides developed the dapivirine ring and supplied rings for this trial.

Presented at the 2021 HIV Research for Prevention (R4P) Conference Virtual, Poster PE14.02, available at https://programme.hivr4p.org/Abstract/Abstract/983

K.J.P., A.L.H., R.S., B.J.G., D.S., U.C., T.P.-P., and N.M.M. have no competing interests. U.M.P. reports consulting agreements from Merck and Co. outside the submitted work. J.M.B. is an employee of Gilead Sciences. J.W.M. reports consulting agreements from Gilead Sciences, Inc., AlloVir, and Abound Bio; share options from Galapagos, NV, and ID Connect; and shares from Abound Bio and MingMed, outside the submitted work.